A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy
Status:
Completed
Trial end date:
2020-09-09
Target enrollment:
Participant gender:
Summary
This study will evaluate the long-term safety and tolerability of VX-659 in triple
combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis
(CF) who are homozygous or heterozygous for the F508del mutation.